Some of you may  may know already this is ASCO week in Chicago. Prof Bill Burhans, our Board & Advisory Board member is acutely aware since he finds himself back in Roswell Park Hospital with all his docs AWOL!  Here at AnCan we are all hoping this is a bit of a false alarm, wish him very well and home soon.

This annual ASCO summer gathering of over 30,000 medics, journalists, advocates and others frequently provides a forum to release important results from clinical trials for all cancers. Prostate cancer is no exception, and we have already seen excellent results from the TITAN trial for the use of apalutamide (Erleada) in metastatic, hormone sensitive disease. In this double blind trial, not only has it outperformed the placebo and now been unblinded, but more importantly there appear to be no statistically significant side effect differences between the two arms. You can read the abstract here.